Lastly, it is currently unknown whether exercise mobilises NK-cells or monocytes in myeloma patients, nor whether the mobilisation of these daratumumab effector cells has the potential to enhance anti-CD38 mAb therapy against circulating myeloma cells. The gene discussed is CD38; the disease is plasma cell myeloma.